Purinosin Tablet (Inosiflex)

Adult dose

(Tablets) 1. Adults: Administer 3～4 g per day of inosiplex orally in divided doses of 500 mg～1 g every 4～6 hours. (Syrup) 1. Adults Administer 3～4 g per day of inosiplex (60～80 mL of this product) orally in divided doses of 500 mg～1g (10～20 mL) every 4～6 hours.

Child dose

(Tablets) 2. Children: Administer 50～100 mg per kg of body weight per day of this product orally in 6 divided doses. (Syrup) 2. Children: Administer 50～100 mg per kg of body weight per day orally in 6 divided doses.

This medication should not be used in patients who have had allergic reactions to this drug or its components. Patients with gout or hyperuricemia or a history of such conditions should use this drug with caution, as it can increase blood uric acid levels and worsen symptoms. Patients with urinary stones or kidney stones should also be cautious, as this drug can elevate uric acid levels and exacerbate stone symptoms. Patients with reduced kidney function should exercise caution when using this medication, as it may delay uric acid excretion. Patients taking digoxin should be careful when using this medication, as it may have a slight effect on the heart. Gastrointestinal symptoms such as dyspepsia, diarrhea, constipation, nausea, vomiting, and abdominal pain may occur after taking this medication. In addition, an increase in red blood cell count or a decrease in white blood cells may be seen, and platelet counts may also rise. Liver function test values may rise, and sometimes liver enzyme levels may also increase. Rarely, allergic reactions such as skin rashes may occur. Metabolic abnormalities causing increased uric acid levels in the blood may develop. This drug can affect the kidneys and urinary system, leading to elevated blood urea nitrogen levels or symptoms such as kidney stones, urinary stones, and polyuria. Neurological symptoms such as headaches, dizziness, fatigue, malaise, irritability, drowsiness, and insomnia have also been reported. Occasionally, arthralgia or rarely interstitial pneumonia can occur. Since this medication can increase uric acid levels in the blood and urine, it is advisable to regularly monitor uric acid levels and kidney function during treatment. This medication does not have particularly severe drug interactions, but it should be avoided in conjunction with cortisone, globulin, immunosuppressants, and antithymocyte globulin. The safety of this medication during pregnancy is uncertain, so women who are pregnant or may become pregnant should use it only when absolutely necessary, especially avoiding its use during the first three months of pregnancy. This drug may also be transmitted through breast milk, so it is advisable to avoid taking this medication during breastfeeding or to discontinue breastfeeding while on the medication. In case of overdose, symptoms such as vomiting, headache, abdominal discomfort, dizziness, and palpitations may occur, but reducing or stopping the dose will resolve the symptoms. In cases of overdose, treatment to alleviate symptoms and supportive care should be provided.

Abdominal discomfort, diarrhea, constipation, gastrointestinal bleeding, nausea, vomiting, stomach pain, increased red blood cells, decreased white blood cells, increased platelets, elevated AST/ALT, elevated γ-GTP, elevated ALP, elevated LDH, rash, hyperuricemia, elevated BUN, kidney stones associated with hypercalcemia, polyuria, urinary stones, headache, dizziness, fatigue, lethargy, irritability, drowsiness, insomnia, joint pain, interstitial pneumonia, palpitations

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 degree Celsius and 30 degrees Celsius.

Appearance

This medicine is a white, round tablet.

Package unit

80 tablets/box [8 tablets/PTPX10]